← Leaderboards
Christian Arthur Heidbreder
Indivior, Inc.
$8,483,680
Attributed
$8,483,680
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,483,680 · 2
By mechanism
UG3$5,779,849 · 1
UH3$2,703,831 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Drug Quality”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Yunda Huang · Fred Hutchinson Cancer Center$52,833,169
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$44,140,914
Research focus
Drug QualityAbsorptionAbstinenceAdme StudyAdmission ActivityAgonistAnimal ModelAddictionBarrier To CareBehaviorBile FluidBloodBuprenorphineCanis FamiliarisCapsuleChild BearingClinical ResearchCuesDevelopment PlansDiagnosisDoseDrug DevelopmentDrug MetabolismDsm-V
Grant awards (5)
Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder$38,402
UH3 · FY2025 · DA · contact PI
Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder$287,245
UH3 · FY2024 · DA · contact PI
Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder$2,378,184
UH3 · FY2023 · DA · contact PI
Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder$2,763,621
UG3 · FY2020 · DA · contact PI
Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder$3,016,228
UG3 · FY2019 · DA · contact PI